AEON Biopharma is a company headquartered in the United States.
AEON Biopharma develops ABP-450 (prabotulinumtoxinA), a branded biosimilar therapeutic botulinum toxin aimed at expanding access to treatments for neuromuscular conditions by providing a lower-cost alternative to Botox.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.